Product Name: Norfloxacin Hydrochloride; Norfloxacin HCL
1-ethyl-6-fluoro-4oxo-1,4-dihydro-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride
Molecular formula and Molecular weight: C16H18FN3O3u00b7HCl=355.80
Property: white crystalline powder; odorless, bitter taste, can absorb moisture in the air, will turn dark in light. Easily soluble in water, slightly soluble in ethanol, almost insoluble in ether, chloroform.
Applicant: It is fluoroquinolones antibacterial, used in the treatment of bacterial or mycoplasma of birds/animals; injection.
Packing: 25kg/cardboard drum; diameter 30cm, height 50cm.
Storage: Sealed, avoid light.
He'nan Kangtai Pharmaceutical Group Corporation, founded in 1993, is located in the picturesque ancient city of Xingyang in He'nan Province. Close to Longhai Railway and Kai-luo highway, the company enjoys convenient transportation. We have registered capital of 52.23 million RMB yuan and total occupied floor area of 100,000 sq. meters as well as 365 employees. Over the past decades, we have been committed to the R & D of hi-tech products, achieving considerable economic and social benefits. And we have ever been honored as He'nan Provincial Hi-tech Enterprise, Example Enterprise in Technological Innovation in He'nan Province, to name just a few. And in the year 2000, we were authorized the self-support imp. & exp. power. Our leading product is norfloxacin(fluperacid) API, which, with an annual output of 1,000mts/a., was listed as He'nan Provincial Key Project in Industrial Application of New and High Technologies. Products have been exported and enjoying good reputation overseas. At present, the manufacturing shops of norfloxacin have been certified by GMP.
In 2005, with an investment of over 8 million RMB yuan, we successfully developed State Class I New Drug--gatifloxacin methanesulfonate, which has reached the world's top level and supplied a gap in the development of quinolones in China. The estimated domestic market share occupied can reach 20% or so.
Overall Development Thought: To be based on the research and development of quinolones antibacterial drugs and intermediates; boost the production of preparations; strive to develop 1 kind of state Class I and Class II new drug respectively in 3-5 years' time, and to become one of the major domestic production bases of quinolones.